Veracyte, which is developing molecular diagnostic tests for thyroid cancer, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The San Francisco, CA-based company, which was founded in 2006 and booked $17 million in sales for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol VCYT. Veracyte initially filed confidentially on August 13, 2013. Morgan Stanley and Leerink Swann are the joint bookrunners on the deal. No pricing terms were disclosed.
